Immunosuppressive mesenchymal cells and methods for forming same

a technology of mesenchymal cells and mesenchymal cells, applied in the field of immunosuppressive mesenchymal cells and methods for forming same, can solve the problem of not being effective in the hit-in-run paradigm

Pending Publication Date: 2019-10-17
THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a method for preparing immunosuppressive mesenchymal stromal cells and primed exosomes for the treatment and prevention of conditions such as cytokine storm, sepsis, autoimmune disease, transplant rejection, graft-vs-host disease, and inflammatory disease. The method involves exposing the cells to a hypoxic culture condition and applying a pro-inflammatory cytokine. The cells can also be primed with a pro-inflammatory cytokine before being exposed to the hypoxic condition. The patent also provides a kit for preparing and administering the immunosuppressive cells and exosomes. The technical effect of the patent is the improved immunomodulatory activity of the primed mesenchymal stromal cells and exosomes, which can be used for the treatment and prevention of various inflammatory and autoimmune diseases.

Problems solved by technology

Assuming that only a fraction of cells are induced and that there is a delay in induction, the “hit” in the hit-in-run paradigm is not as effective as it would be if the cells started off by being homogeneously immunosuppressive at the time of injection.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunosuppressive mesenchymal cells and methods for forming same
  • Immunosuppressive mesenchymal cells and methods for forming same
  • Immunosuppressive mesenchymal cells and methods for forming same

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0123]Here we propose a specific in vitro priming protocol of MSCs that can enhance their immunosuppressive qualities. We first compared combinations of three different stimuli: hypoxia (1% O2), IFN-γ (100 ng / mL), and IL-10 (10 ng / mL). Based on gene expression studies for >12 immunosuppressive / protective factors, the conditioning regimen of the combination of IFN-γ and hypoxia for two days led to the target expression of genes known to induce immunosuppression. Those with the greatest fold increase post-stimulation included PDL1, IDO, HLA-G, and COX2, the first two being responsive to the IFN-γ component, while the latter two were mainly upregulated by hypoxia. Importantly, the expression of these genes remained increased over baseline for over one-week post-stimulation, a phenomenon that could be re-capitulated upon re-stimulation.

[0124]Here, we explored combined IFN-γ and hypoxia priming of human MSCs. After 48 h of stimulation, several immunosuppressive factors were upregulated, ...

example 2

[0127]Genes induced by dual priming stay upregulated for up to one week and can be re-induced. To better understand how gene expression changes would persist in the setting of therapeutic application, dual primed MSCs were returned to control conditions, and qRT-PCR for HLA-G, IDO, PD-L1, and COX-2 was performed after 4 days and 7 days. Notably and unexpectedly, for all three MSC donors, HLA-G, IDO, and PD-L1 remained significantly upregulated after being returned to control conditions for 7 days, although a noticeable drop from their peak expression could be seen by day 4 (FIG. 4B). Consistent with the kinetic studies that showed a decline in COX-2 expression by 48 hours, COX-2 expression continued to mildly decline for MSCs that had previously been kept in either control or priming conditions. Since primed MSCs may be re-exposed to inflammatory and hypoxic cues in the patient, the priming regimen was repeated after being returned to control conditions for seven days, and the induc...

example 3

[0128]Dual priming induces immunomodulatory factors at the protein level. In FIG. 6, data are shown for various 48-hour priming regimens. Histograms are from a representative experiment. For clarity, only control MSCs vs. dual primed MSCs are shown on the left, whereas all conditions are shown on the right. The table at the bottom of FIG. 6 shows the mean fluorescence intensity (MFI) of the primed MSCs normalized to the MFI of Control MSCs for n=3 experiments. Significance is shown as (*) for IFN-γ vs. hypoxia stimulation and (t) for IFN-γ vs. dual stimulation. Flow cytometry for HLA-G, IDO, PD-L1, and COX-2 confirmed that they were upregulated at the protein level after dual priming for 48 hours (FIG. 6, top). Considering both single factor and dual factor priming regimens, there were some different patterns at the protein level as compared with the initial PCR findings (FIG. 6, bottom). At the protein level, IDO had slightly more induction by dual priming (although nonsignificant)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Temperatureaaaaaaaaaa
Fractionaaaaaaaaaa
Timeaaaaaaaaaa
Login to View More

Abstract

The present disclosure describes immunosuppressive mesenchymal stromal cells and exosomes secreted from immunosuppressive mesenchymal stromal cells, and methods for their preparation. The disclosure also describes methods for treating subjects or preventing subjects at risk for conditions by administering the immunosuppressive mesenchymal stromal cells or secreted exosomes. The present disclosure also describes kits for preparing immunosuppressive mesenchymal stromal cells and exosomes secreted from immunosuppressive mesenchymal stromal cells.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of International Application No. PCT / US2017 / 058686 filed on Oct. 27, 2017, which claims the benefit of U.S. Provisional application No. 62 / 413,696 filed on Oct. 27, 2016, and claims the benefit of U.S. Provisional application No. 62 / 530,617 filed on Jul. 10, 2017, both of which are incorporated by reference herein.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH[0002]This invention was made with government support under grant numbers UH3EB17103 and EB002520, awarded by the National Institute of Biomedical Imaging and Bioengineering. The government has certain rights in the invention.SEQUENCE LISTING[0003]The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Oct. 25, 2017, is named 16-50199-WO_SL.txt and is 7,568 bytes in size.BACKGROUND OF THE INVENTION[0004]Mesenchym...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/28C12N5/0775C07K14/725A61K35/17A61P37/00A61P29/00
CPCA61P37/00C12N5/0663A61K35/17C07K14/7051A61P29/00C12N2500/10C12N5/0668A61K35/28C12N5/0665C12N2500/02C12N5/0667C12N2500/46C12N2501/24A61K45/06A61P37/06C12N2501/231A61K39/4621A61K39/461A61K39/46433C12N2523/00
InventorWOBMA, HOLLYKANAI, MARIKOVUNJAK-NOVAKOVIC, GORDANA
OwnerTHE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK